Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Silver Spruce Resources

    MCap

    CAD2m

    Last close

    CAD0.02

    ▲ 0.01 (100.00%)

    Biodexa Pharmaceuticals

    MCap

    USD2m

    Last close

    USD5.11

    ▲ 1.61 (46.00%)

    Pharnext

    MCap

    EUR1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

BB Biotech (BION)

Currency in CHF

Last close As at 01/12/2023

CHF38.10

▲ −0.25 (−0.65%)

Market capitalisation

CHF2,125m

BB Biotech, a Switzerland-based investment company, targets long-term capital growth from biotechnology companies developing and marketing innovative drugs. At least 90% of the portfolio is held in listed companies, primarily those that already have products on the market or promising drug candidates in advanced stages of development. BION is benchmarked against the Nasdaq Biotech Index (in CHF) but managed on a bottom-up basis, with a focused c 20–35 stock portfolio.

Latest Insights

View More

Investment Companies | Update

BB Biotech — A cutting-edge sector and a high dividend

Investment Companies | Update

BB Biotech — Picking growth at good value

Investment Companies | edison tv

BB Biotech – executive interview

Investment Companies | Review

BB Biotech — Great valuation potential
Healthcare business concept, Medical examination and growth graph data of business on tablet with doctor's health report clipboard on background.
Visit Website

Equity Analyst

Joanne Collins

Joanne Collins

Analyst, Investment Trusts

Key Management

  • Claude Mikkelsen

    Director of IR

  • Daniel Koller

    Head of investment management

  • Dr Silvia Siegfried-Schanz

    Director of IR

  • Erich Hunziker

    Chairman

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 6.1 (4.6) (35.0)
Relative 1.4 (1.9) (33.3)
52 week high/low CHF60.7/CHF35.6

Overview

BB Biotech (BION) offers investors exposure to the innovative, rapidly expanding biotech sector. BION is the largest biotech investor among its investment company peers. It invests in high-quality biotech assets that target substantial market opportunities. BION’s managers are optimistic about the outlook for the sector. They believe sentiment towards the sector should improve as interest rates peak and begin to decline. Meanwhile, they expect to see ongoing fundamental progress by portfolio holdings, with several due to reach key regulatory, clinical or commercial milestones over coming months. In addition, historically low valuations have created opportunities to add or top up exposure to interesting companies at attractive prices. BION differentiates itself from its peers by its highly competitive dividend policy – it pays a dividend equivalent to 5% of the average share price over December each year.

Research

Review

Investment Companies

BB Biotech — High-conviction specialist with impressive record

Review

Investment Companies

BB Biotech — Update 27 February 2017

Investment Companies

Review

BB Biotech — Strong focus on emerging clinical areas

edison tv

Investment Companies

Bitesize Briefings – BB Biotech

Review

Investment Companies

BB Biotech AG — Update 8 February 2016

thematic

TMT

ESG, moving beyond the box tick

thematic

Investment Companies

The case for US capital markets

thematic

Investment Companies

Value Investing: Living with the reality, waiting for the inevitable

thematic

Consumer

Illuminator: August Update

thematic

Investment Companies

Post Woodford- A spotlight on smaller company liquidity

thematic

Investment Companies

How to buy and sell investment trusts

thematic

Investment Companies

Types of investment trusts

thematic

Consumer

Deutsche Börse Eigenkapitalforum 2014 Research Guide

thematic

Investment Companies

Investment Trusts Quarterly: Biotechnology & healthcare trusts

thematic

Investment Companies

Investment Trusts Quarterly: Growth and income